Recombinant interleukin-2 and other types of treatment of advanced malignant melanoma.
Interleukin-2 has demonstrated significant and consistent activity against melanoma even in patients who have been treated previously with other modalities. This paper reviews local treatment, systemic treatment with single-agent, combination, and high-dose chemotherapy, and new agents; biologic modifier therapy, including tumor vaccines and active specific immunization, and interferons; and recombinant interleukin-2, which has activity when used alone, with lymphokine-activated killer cells, chemotherapy, or biologic modifiers. Tumor response, predictors of response, and survival are also discussed.
Thatcher
N
N
Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Withington, Manchester, England.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D008545:Melanoma / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use
D000970:Antineoplastic Agents; D007376:Interleukin-2; D011994:Recombinant Proteins